Dupixent 200 MG/1.14 ML pen 1.14ML
Ended Awarded
- Contract number
- SPE2DB25FE3L1
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $27,943
Award facts
- Contract value 100% obligated
- $27,943.05 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $27,943.05 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pen injectors on August 28, 2025, with completion targeted for August 29, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and represents performance at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly for the Defense Health Agency and other government healthcare systems. This specific delivery order for Dupixent—a biologic medication used to treat conditions such as atopic dermatitis and eosinophilic asthma—demonstrates the company's role in supplying specialized pharmaceutical products through the DLA's Medical Supply Chain. The contract reflects AmerisourceBergen's demonstrated capability to meet federal procurement requirements through open competition and positions the company within DLA's planned Pharmaceutical Prime Vendor Global Program Generation V contracts, which will involve multiple regional awards across several contractors.
Quick answers
Who was awarded contract SPE2DB25FE3L1?
SPE2DB25FE3L1 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 28, 2025.
How much is contract SPE2DB25FE3L1 worth?
The government has obligated $27,943 on SPE2DB25FE3L1.
Is contract SPE2DB25FE3L1 an order under another contract?
Yes. SPE2DB25FE3L1 is a delivery order under SPE2DB20D1100, an indefinite delivery contract.
Was contract SPE2DB25FE3L1 competed?
The extent of competition for SPE2DB25FE3L1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award